Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BHVN
- Price
- 14.46
- Stock movement down
- -0.02 (-0.14%)
- Company name
- Biohaven Pharmaceutical Holding Co Ltd
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.55B
- Ent value
- 1.66B
- Price/Sales
- -
- Price/Book
- 4.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -1.39%
- 1 year return
- -63.07%
- 3 year return
- -53.50%
- 5 year return
- -27.56%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BHVN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 4.91 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 105.79M |
| EPS (TTM) | -8.52 |
| FCF per share (TTM) | -5.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -2.87M |
| Operating income (TTM) | -848.89M |
| Net income (TTM) | -804.34M |
| EPS (TTM) | -8.52 |
| EPS (1y forward) | -5.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 84.39M |
| Net receivables | 5.32M |
| Total current assets | 440.50M |
| Goodwill | 1.39M |
| Intangible assets | 18.40M |
| Property, plant and equipment | 58.38M |
| Total assets | 510.52M |
| Accounts payable | 19.74M |
| Short/Current long term debt | 28.99M |
| Total current liabilities | 152.29M |
| Total liabilities | 194.52M |
| Shareholder's equity | 316.01M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -526.59M |
| Capital expenditures (TTM) | 4.47M |
| Free cash flow (TTM) | -531.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -254.53% |
| Return on Assets | -157.55% |
| Return on Invested Capital | -251.60% |
| Cash Return on Invested Capital | -166.12% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 14.57 |
| Daily high | 14.69 |
| Daily low | 14.23 |
| Daily Volume | 1.10M |
| All-time high | 149.26 |
| 1y analyst estimate | 47.14 |
| Beta | 3.50 |
| EPS (TTM) | -8.52 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 18 Nov 2025 |
Downside potential
Loading...
Downside potential data
| BHVN | S&P500 | |
| Current price drop from All-time high | -90.16% | -1.46% |
| Highest price drop | -95.78% | -56.47% |
| Date of highest drop | 30 Sep 2022 | 9 Mar 2009 |
| Avg drop from high | -39.00% | -10.99% |
| Avg time to new high | 24 days | 12 days |
| Max time to new high | 731 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.55B
Marketcap category
Small-cap
Description
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and c
Employees
256
Website
Investor relations
-
SEC filings
CEO
Vlad Coric
Country
USA
City
New Haven
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page